Breaking News

Alexza Pharma Appoints Ops EVP

By Kristin Brooks | February 25, 2014

Lippe responsible for global strategic operations

Robert A. Lippe has been appointed executive vice president of operations and chief operations officer at Alexza Pharmaceuticals. In this newly created position, Mr. Lippe is responsible for the company's global operations, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and partner management, technology transfer, facilities, sustainment engineering and IT, in support of the company's product and technology portfolio.
 
Mr. Lippe brings more than 20 years of experience in operations with multinational biopharmaceutical companies and national research labs. Mr. Lippe joins the company from Ironwood Pharmaceuticals, where he served as head of global operations and operational excellence. Prior to Ironwood, Mr. Lippe worked for Genentech, where he served as head of manufacturing for the company's Vacaville, CA operations. Mr. Lippe also held multiple positions at Genentech in strategic operations, drug substance and drug product manufacturing, and facilities. Mr. Lippe spent 10 years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard.
 
"We are pleased to welcome Rob to our senior management team," said Thomas B. King, president and chief executive officer. "Rob brings an extensive set of operational skills, along with a strategic sense and outlook. We look forward to his contributions as we continue the growth of the company through the global launch of ADASUVE and expansion of our product candidate pipeline."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important